subtypes distinguishes our lead compounds from existing
benzodiazepine products that act on all four subtypes, and
from the newer selective modulators that act on one site
of the GABA complex. We believe that our identified targets
may have the potential to provide anxiolytic effect without
sedation.
D-amino acid oxidase inhibitors are believed to offer therapeutic
potential for treatment of cognitive disorders, schizophrenia
and pain. Our discovery program has identified selective
leads that may be applicable for treating different CNS
disorders and have been shown to be potent and efficacious
in preclinical models.
We are also conducting a discovery program targeting the
m1 receptor. Selective m1 agonists are thought to hold promise
as a new mechanism for treatment of psychosis, cognition
and pain.
Our goal from these preclinical discovery programs is to
yield new Investigational New Drug (IND) applications each
year, creating internal, sustained product flow.
1
National Institute of Mental Health web site http://www.nimh.nih.gov/publicat/depression.cfm,
accessed February 8, 2007
2
Paul E. Greenberg et al., “The Economic Burden of Depression
in the United States: How Did it Change Between 1990 and
2000?”
J Clin Psychiatry 2003;64:1465-1475
